¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"competitive binding assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • protein,actin-binding
    ¾×ƾ-°áÇÕ(´Ü¹é)
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • retinol-binding protein
    ·¹Æ¼³î°áÇմܹé(Áú)(·¹Æ¼³î Ì¿ùêÓ±ÛÜòõ)
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇÕ±Û·Îºí¸°
  • sex-hormone binding globulin
  • testosterone-binding globulin
    Å×½ºÅ佺Å×·Ð °áÇմܹé
  • thyroid-binding globulin
  • thyroxin binding globulin
    Ƽ·Ï½Å°áÇձ۷κҸ°.
  • thyroxin binding prealbumin
    Ƽ·Ï½Å°áÇÕÇÁ¸®¾ËºÎ¹Î.
  • thyroxin binding protein
    Ƽ·Ï½Å°áÇմܹéÁú(¡­Ì¿ùêÓ±ÛÜòõ).
  • thyroxine -binding globulin
    Ƽ·Ï½Å°áÇÕ±Û·Îºí¸°
  • thyroxine-binding prealbumin
    Ƽ·Ï½Å°áÇÕÇÁ¸®¾ËºÎ¹Î
  • total iron binding capacity
    ÃÑö°áÇÕ´É
  • total iron binding capacity=TIBC
    ÃÑö°áÇÕ´É
  • unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É(¡­ôÑÌ¿ùêÒö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • nonexclusive binding
    ºñ¹èŸ°áÇÕ(ÞªÛÉöâÌ¿ùê)
  • nonexclusive binding coefficient
    ºñ¹èŸ°áÇÕ»ó¼ö(ÞªÛÉöâÌ¿ùêßÈâ¦)
  • nucleotide-binding domain
    ´©Å¬¸®¿ÀŸÀÌµå °áÇÕ¿µ¿ª(Ì¿ùêÖÅæ´)
  • retinol-binding protein
    ·¹Æ¼³î °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • ribosome binding site
    ¶óÀ̺¸¼Ø °áÇÕ(Ì¿ùê)ÀÚ¸®
  • ribosome binding technique
    ¶óÀ̺¸¼Ø °áÇÕ¼ú(Ì¿ùêâú)
  • sex hormoe binding globulin
    ¼º(àõ)È£¸£¸ó °áÇÕ(Ì¿ùê)±Û·ÎºÒ¸°
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • single-strand binding protein
    ¿Ü°¡´Ú °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • single-stranded DNA binding protein
    ¿Ü°¡´Ú DNA °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • substrate-binding site
    ±âÁú°áÇÕ (ÐñòõÌ¿ùê) ÀÚ¸®
  • testosterone-estradiol-binding globulin
    Å×½ºÅ佺Å×·Ð-¿¡½ºÆ®¶ó´ÙÀ̿à °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • thyroxine-binding globulin
    ŸÀ̷ϽŰáÇÕ(Ì¿ùê) ±Û·ÎºÒ¸°
  • thyroxine-binding prealbumin
    ŸÀ̷ϽŰáÇÕ(Ì¿ùê) ÇÁ¸®¾ËºÎ¹Î
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
PBP penicillin-binding protein; porphyrin biosynthesis pathway; prostate-binding protein; pseudobulbar p...
RBP retinol-binding protein; riboflavin-binding protein
SBP schizobipolar; serotonin-binding protein; spontaneous bacterial peritonitis; steroid-binding plasma ...
SSB short spike burst; sicca syndrome B; single-strand break; single-stranded binding [protein]; stereos...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
EIA Electro Immuno-Assay
EMSA Electrophoresis mobility shift assay
EMSA Electrophoretic Mobility Shift Assay
EMSA Electrophoretic gel mobility shift assay
EIA Enzyme Immune Assay
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
androgen-binding proteins Carrier proteins produced in the sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. Participate in the transport of androgens; include also synthetic androgens binding proteins.
(12 Dec 1998)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
binding <biochemistry, chemistry, molecular biology> The adherence of molecules to one another, for example, enzymes to substrates, antibodies to antigens, DNA strands to their complementary strands.
Binding occurs because the shape and chemical natures of parts of the molecules surfaces are complementary. A common metaphor is the "lock-and-key," used to describe how enzymes fit around their substrate.
(14 Nov 1997)
binding constant <chemistry> Reciprocal of dissociation constant. A measure of the extent of a reversible association between two molecular species at equilibrium.
(18 Nov 1997)
binding energy <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule.
(16 Dec 1997)
binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
(12 Dec 1998)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
calcium-binding protein <biochemistry> There are two main groups of calcium binding proteins, those that are similar to calmodulin and are called EF hand proteins and those that bind calcium and phospholipid (e.g. Lipocortin) and that have been grouped under the generic name of annexins.
Many other proteins will bind calcium, although the binding site usually has considerable homology with the calcium-binding domains of calmodulin. They can act as transport proteins, regulator proteins or activator proteins.
There is also a vitamin D-dependent variant which is a protein that plays a fundamental role in the vitamin d mediated transport of calcium in reptiles, amphibians, birds and mammals. It is found in the intestine, kidneys, egg shell gland, brain, and possibly other organs. Its molecular weight is species dependent.
(12 May 2002)
calmodulin-binding proteins Proteins which bind calmodulin. They are found in many tissues and have a variety of functions including f-actin cross-linking properties, inhibition of cyclic nucleotide phosphodiesterase and calcium and magnesium atpases.
(12 Dec 1998)
cap binding protein <molecular biology, protein> Protein (24 kD) with affinity for cap structure at 5' end of mRNA that probably assists, together with other initiation factors, in binding the mRNA to the 40S ribosomal subunit. Translation of mRNA in vitro is faster if it has a cap binding protein.
(18 Nov 1997)
galactose binding protein <protein> A bacterial periplasmic protein, most studied in E. Coli, that acts both as a sensory element in the detection of galactose as a chemotactic signal and in the uptake of the sugar.
(18 Nov 1997)
Raji cell binding test <investigation> A test for the detection of soluble IgG antigen complexes. Raji cells are a line of EBV transformed lymphocytes with surface Fc receptors. Complexes are detected by their ability to compete with a radiolabelled aggregated IgG for binding to the cells.
(18 Nov 1997)
maltose binding protein <protein> Protein of the bacterial (E. Coli) surface that links with MCP II and is involved in the chemotactic response to maltose, probably derived from a similar protein that links with a trans membrane transport system.
(18 Nov 1997)
vitamin d-binding protein An alpha-globulin found in the plasma of man and other vertebrates. It is apparently synthesised in the liver and carries vitamin d and its metabolites through the circulation and mediates the response of tissue. It is also known as group-specific component (gc). Gc subtypes are used to determine specific phenotypes and gene frequencies. These data are employed in the classification of population groups, paternity investigations, and in forensic medicine.
(12 Dec 1998)
cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á